{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:53:29Z","timestamp":1793566409664,"version":"4.5.0"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,1,31]],"date-time":"2007-01-31T00:00:00Z","timestamp":1170201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence of metabolic syndrome among patients with gout and to examine the association between the 2 conditions in a nationally representative sample of US adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using data from 8,807 participants age \u226520 years in the Third National Health and Nutrition Examination Survey (1988\u20131994), we determined the prevalence of metabolic syndrome among individuals with gout and quantified the magnitude of association between the 2 conditions. We used both the revised and original National Cholesterol Education Program Adult Treatment Panel III (NCEP\/ATP III) criteria to define metabolic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence (95% confidence interval [95% CI]) of metabolic syndrome according to revised NCEP\/ATP III criteria was 62.8% (51.9\u201373.6) among individuals with gout and 25.4% (23.5\u201327.3) among individuals without gout. Using 2002 census data, \u223c3.5 million US adults with a history of gout have metabolic syndrome. The unadjusted and age\u2010 and sex\u2010adjusted odds ratios (95% CI) of metabolic syndrome for individuals with gout were 4.96 (3.17\u20137.75) and 3.05 (2.01\u20134.61), respectively. With the original NCEP\/ATP criteria, the corresponding prevalences were slightly lower, whereas the corresponding odds ratios were slightly higher. The stratified prevalences of metabolic syndrome by major associated factors of gout (i.e., body mass index, hypertension, and diabetes) remained substantially and significantly higher among those with gout than those without gout (all <jats:italic>P<\/jats:italic> values &lt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings indicate that the prevalence of metabolic syndrome is remarkably high among individuals with gout. Given the serious complications associated with metabolic syndrome, this frequent comorbidity should be recognized and taken into account in long\u2010term treatment and overall health of individuals with gout.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.22466","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T05:54:12Z","timestamp":1170482052000},"page":"109-115","source":"Crossref","is-referenced-by-count":398,"title":["Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey"],"prefix":"10.1002","volume":"57","author":[{"given":"Hyon K.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl S.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Curhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"e_1_2_6_3_2","unstructured":"American Heart Association. Metabolic syndrome: new guidance for prevention and treatment. URL:http:\/\/www.americanheart.org\/presenter.jhtml?identifier=3033454."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009572"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1769"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.356"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.509"},{"key":"e_1_2_6_8_2","first-page":"1350","article-title":"Gout, diet, and the insulin resistance syndrome","volume":"29","author":"Fam AG","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117634"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1047-2797(97)00204-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470210076036"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000129082.42094.fc"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.6.1029"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2003.12.007"},{"key":"e_1_2_6_16_2","volume-title":"Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01\u20103670","author":"National Institutes of Health","year":"2001"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"key":"e_1_2_6_18_2","volume-title":"The Third National Health and Nutrition Examination Survey (NHANES III 1988\u201094) reference manuals and reports [CD\u2010ROM]","author":"Centers for Disease Control and Prevention","year":"1996"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000108926.04022.0C"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0920051"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(96)00098-2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.7.539"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1536\/jhj.44.527"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90163-4"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00745-0"},{"key":"e_1_2_6_27_2","first-page":"F374","article-title":"Effects of intravenous adenosine on renal function in healthy human subjects","volume":"271","author":"Balakrishnan VS","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_6_28_2","first-page":"F504","article-title":"A potential role for endogenous adenosine in control of human glomerular and tubular function","volume":"265","author":"Balakrishnan VS","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1681\/ASN.V651491","article-title":"Adenosine and renal sodium handling: direct natriuresis and renal nerve\u2010mediated antinatriuresis","volume":"6","author":"Fransen R","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400196"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.4.537"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441801"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199813030-00006"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(92)90111-M"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.572"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg341"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.14.1723"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.14.1758"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2444"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-9-200311040-00011"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000069700.62727.C5"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(88)90127-8"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035700"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16000-5"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22466","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T12:30:45Z","timestamp":1700051445000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,31]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2,15]]}},"alternative-id":["10.1002\/art.22466"],"URL":"https:\/\/doi.org\/10.1002\/art.22466","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,31]]}}}